Grant ID CP130013
Awarded On February 19, 2014
Title Clinical Development and Commercialization of Oncolytic Adenovirus for Treating Malignant Glioma
Program Product Development Research
Award Mechanism Company Commercialization
Institution/Organization DNAtrix, Inc.
Principal Investigator/Program Director Frank Tufaro
Cancer Sites Brain and Other Nervous System
Contracted Amount $10,813,623
Lay Summary

DNAtrix, Inc. is a Texas-based company developing modified viruses for the treatment of the most aggressive type of brain cancer called glioblastoma. Scientists have modified the common cold virus called adenovirus in 2 specific ways so that it can recognize and kill cancer cells very effectively without harming normal brain. The first product of its kind, called Delta-24-RGD, has just completed its first big test in more than 35 patients with GB at the MD Anderson Cancer Center in Houston.

Many patients with GB who participated had a remarkable response to the therapy, with evidence of tumor killing and improved survival. Perhaps equally important, there were no safety concerns or side-eff...

Read More